BCRF Researcher Profile:
Meet Ephrat Levy-Lahad, MD

"Medicine and science are areas where the 'human good' is so obvious that it becomes easier to overcome some of the obstacles often associated with political conflict, like the Israeli/Palestinian situation. We are very proud of our joint efforts with Palestinian scientists and are thankful to BCRF for inspiring it." Read More...

Tribute to Evelyn H. Lauder at San Antonio Breast Cancer Symposium 2011

Approximately, 8,000 participants from more than 90 countries attended the 34th San Antonio Breast Cancer Symposium (SABCS), the world's largest annual breast cancer meeting. C. Kent Osborne, MD (Baylor College of Medicine), Co-Director of SABCS and BCRF grantee, opened the proceedings with a tribute to Evelyn H. Lauder, founder of The Breast Cancer Research Foundation.

Larry Norton, MD (Memorial Sloan-Kettering Cancer Center), BCRF Scientific Director, then reflected on the genesis of the Foundation. Explaining the link between the beauty industry and breast cancer research, respectively where Evelyn Lauder had built her career and philanthropic focus, Dr. Norton expressed, "Defiance — not denial — of physical imperfections, of aging, and of illness" was what motivated Evelyn Lauder to found BCRF. In addition to her dedication to "those who need our help," what made Evelyn Lauder remarkable was "her confidence in us, our ability as dedicated physicians and scientists," which led to her commitment to funding scientific inquiries and encouraging creativity.Click through to see a video of Dr. Norton's address.

Report from the 34th Annual San Antonio Breast Cancer Symposium, December 6-10, 2011

As harbinger for future success, several advances in clinical care for metastatic breast cancer were reported at this year's meeting. The limiting step of any cancer therapy is resistance. When a new therapy is applied, patients either do not respond from the very beginning or initially benefit from the therapy but eventually develop resistance. Based on earlier studies funded in part by BCRF, researchers have designed and developed clinical trials to see if various combinations of existing therapies would overcome resistance and improve results for patients. Results from two large-scale, international clinical trials were announced at SABCS and published in the New England Journal of Medicine.

Read More...